BRAZILIAN IBD STUDY GROUP POSITION STATEMENT ON SARS-COV2 VACCINATION.

Natália Souza Freitas Queiroz Fábio Vieira Teixeira Caio Cesar Furtado Freire Marina Pamponet Motta Marcela Almeida Menezes de Vasconcellos Liliana Andrade Chebli Rogério Saad Hossnenull null

Published in: Arquivos de gastroenterologia (2021)

Mass vaccination offers the best strategy to fight against COVID-19 pandemic, and SARS-CoV2 vaccines are being approved in several countries for emergency use. In Brazil, vaccine approval is expected in the next few days, however potential concerns exist regarding vaccine recommendations for specific populations, such as patients with inflammatory bowel disease (IBD). To address these questions, the Brazilian IBD Study Group (GEDIIB) provides this practical advice with key recommendations about the COVID-19 vaccines in IBD population.

Keyphrases

sars cov
patients with inflammatory bowel disease
emergency department
coronavirus disease
ulcerative colitis
healthcare
drug administration